Medical Care
Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Research Report 2025
- Jul 10, 25
- ID: 365137
- Pages: 100
- Figures: 95
- Views: 10
The global market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing was valued at US$ 6015 million in the year 2024 and is projected to reach a revised size of US$ 10886 million by 2031, growing at a CAGR of 8.9% during the forecast period.
High-potent oral solid dosage (OSD) contract manufacturing refers to specialized third-party manufacturing services for oral solid drugs containing highly potent active pharmaceutical ingredients (HPAPIs), such as oncology agents, hormones, and immunosuppressants. These services typically include formulation development, scale-up, clinical supply, and commercial manufacturing of tablets, capsules, or granules under strict containment and cGMP-compliant conditions. Due to the toxicity and potency of HPAPIs (with occupational exposure limits often <10 µg/m³), facilities must be equipped with advanced containment technologies, segregated equipment, and robust cross-contamination controls. This niche segment is rapidly growing in response to the increasing demand for targeted therapies and complex small-molecule drugs.
North American market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing in Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing include Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing.
The High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, by Formulation Technologies and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Catalent
Thermo Fisher Scientific
Lonza
Siegfried
Recipharm
Boehringer Ingelheim
WuXi AppTech
WuXi Biologics
Fareva
Samsung Biologics
Aenova
Delpharm
Strides Pharma
Piramal
Famar
Curia
Jubilant
Vetter
AGC Pharma Chemicals
Asymchem
Segment by Type
Tablets
Hard Gelatine Capsules
Sublingual Tablets
Special Solid Dosage Forms
Press Coated Tablets
Other
Segment by Formulation Technologies
Fluid Bed Granulation
Roller Compaction
Direct Compression
Hot Melt Extrusion
Spray Drying
Microencapsulation
Segment by Application
Cancer
Hormonal Disorders
Autoimmune Diseases
Neurological Disorders
Pain Management
Other Therapy Areas
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Formulation Technologies etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
High-potent oral solid dosage (OSD) contract manufacturing refers to specialized third-party manufacturing services for oral solid drugs containing highly potent active pharmaceutical ingredients (HPAPIs), such as oncology agents, hormones, and immunosuppressants. These services typically include formulation development, scale-up, clinical supply, and commercial manufacturing of tablets, capsules, or granules under strict containment and cGMP-compliant conditions. Due to the toxicity and potency of HPAPIs (with occupational exposure limits often <10 µg/m³), facilities must be equipped with advanced containment technologies, segregated equipment, and robust cross-contamination controls. This niche segment is rapidly growing in response to the increasing demand for targeted therapies and complex small-molecule drugs.
North American market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing in Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing include Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing.
The High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, by Formulation Technologies and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Catalent
Thermo Fisher Scientific
Lonza
Siegfried
Recipharm
Boehringer Ingelheim
WuXi AppTech
WuXi Biologics
Fareva
Samsung Biologics
Aenova
Delpharm
Strides Pharma
Piramal
Famar
Curia
Jubilant
Vetter
AGC Pharma Chemicals
Asymchem
Segment by Type
Tablets
Hard Gelatine Capsules
Sublingual Tablets
Special Solid Dosage Forms
Press Coated Tablets
Other
Segment by Formulation Technologies
Fluid Bed Granulation
Roller Compaction
Direct Compression
Hot Melt Extrusion
Spray Drying
Microencapsulation
Segment by Application
Cancer
Hormonal Disorders
Autoimmune Diseases
Neurological Disorders
Pain Management
Other Therapy Areas
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Formulation Technologies etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tablets
1.2.3 Hard Gelatine Capsules
1.2.4 Sublingual Tablets
1.2.5 Special Solid Dosage Forms
1.2.6 Press Coated Tablets
1.2.7 Other
1.3 Market by Formulation Technologies
1.3.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Formulation Technologies: 2020 VS 2024 VS 2031
1.3.2 Fluid Bed Granulation
1.3.3 Roller Compaction
1.3.4 Direct Compression
1.3.5 Hot Melt Extrusion
1.3.6 Spray Drying
1.3.7 Microencapsulation
1.4 Market by Application
1.4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth by Application: 2020 VS 2024 VS 2031
1.4.2 Cancer
1.4.3 Hormonal Disorders
1.4.4 Autoimmune Diseases
1.4.5 Neurological Disorders
1.4.6 Pain Management
1.4.7 Other Therapy Areas
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Perspective (2020-2031)
2.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Growth Trends by Region
2.2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Region (2020-2025)
2.2.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Region (2026-2031)
2.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Dynamics
2.3.1 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Industry Trends
2.3.2 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Drivers
2.3.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Challenges
2.3.4 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Revenue
3.1.1 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Revenue (2020-2025)
3.1.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Players (2020-2025)
3.2 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue
3.4 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Concentration Ratio
3.4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue in 2024
3.5 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Head office and Area Served
3.6 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Product and Application
3.7 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Breakdown Data by Type
4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Type (2020-2025)
4.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Type (2026-2031)
5 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Breakdown Data by Application
5.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Application (2020-2025)
5.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
6.2 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
6.4 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
7.2 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
7.4 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
8.2 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025)
8.4 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
9.2 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
9.4 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
10.2 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
10.4 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.1.4 Catalent Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.1.5 Catalent Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Details
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.2.4 Thermo Fisher Scientific Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Lonza
11.3.1 Lonza Company Details
11.3.2 Lonza Business Overview
11.3.3 Lonza High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.3.4 Lonza Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.3.5 Lonza Recent Development
11.4 Siegfried
11.4.1 Siegfried Company Details
11.4.2 Siegfried Business Overview
11.4.3 Siegfried High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.4.4 Siegfried Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.4.5 Siegfried Recent Development
11.5 Recipharm
11.5.1 Recipharm Company Details
11.5.2 Recipharm Business Overview
11.5.3 Recipharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.5.4 Recipharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.5.5 Recipharm Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.6.4 Boehringer Ingelheim Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.6.5 Boehringer Ingelheim Recent Development
11.7 WuXi AppTech
11.7.1 WuXi AppTech Company Details
11.7.2 WuXi AppTech Business Overview
11.7.3 WuXi AppTech High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.7.4 WuXi AppTech Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.7.5 WuXi AppTech Recent Development
11.8 WuXi Biologics
11.8.1 WuXi Biologics Company Details
11.8.2 WuXi Biologics Business Overview
11.8.3 WuXi Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.8.4 WuXi Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.8.5 WuXi Biologics Recent Development
11.9 Fareva
11.9.1 Fareva Company Details
11.9.2 Fareva Business Overview
11.9.3 Fareva High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.9.4 Fareva Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.9.5 Fareva Recent Development
11.10 Samsung Biologics
11.10.1 Samsung Biologics Company Details
11.10.2 Samsung Biologics Business Overview
11.10.3 Samsung Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.10.4 Samsung Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.10.5 Samsung Biologics Recent Development
11.11 Aenova
11.11.1 Aenova Company Details
11.11.2 Aenova Business Overview
11.11.3 Aenova High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.11.4 Aenova Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.11.5 Aenova Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Details
11.12.2 Delpharm Business Overview
11.12.3 Delpharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.12.4 Delpharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.12.5 Delpharm Recent Development
11.13 Strides Pharma
11.13.1 Strides Pharma Company Details
11.13.2 Strides Pharma Business Overview
11.13.3 Strides Pharma High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.13.4 Strides Pharma Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.13.5 Strides Pharma Recent Development
11.14 Piramal
11.14.1 Piramal Company Details
11.14.2 Piramal Business Overview
11.14.3 Piramal High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.14.4 Piramal Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.14.5 Piramal Recent Development
11.15 Famar
11.15.1 Famar Company Details
11.15.2 Famar Business Overview
11.15.3 Famar High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.15.4 Famar Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.15.5 Famar Recent Development
11.16 Curia
11.16.1 Curia Company Details
11.16.2 Curia Business Overview
11.16.3 Curia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.16.4 Curia Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.16.5 Curia Recent Development
11.17 Jubilant
11.17.1 Jubilant Company Details
11.17.2 Jubilant Business Overview
11.17.3 Jubilant High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.17.4 Jubilant Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.17.5 Jubilant Recent Development
11.18 Vetter
11.18.1 Vetter Company Details
11.18.2 Vetter Business Overview
11.18.3 Vetter High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.18.4 Vetter Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.18.5 Vetter Recent Development
11.19 AGC Pharma Chemicals
11.19.1 AGC Pharma Chemicals Company Details
11.19.2 AGC Pharma Chemicals Business Overview
11.19.3 AGC Pharma Chemicals High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.19.4 AGC Pharma Chemicals Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.19.5 AGC Pharma Chemicals Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Details
11.20.2 Asymchem Business Overview
11.20.3 Asymchem High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.20.4 Asymchem Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.20.5 Asymchem Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tablets
1.2.3 Hard Gelatine Capsules
1.2.4 Sublingual Tablets
1.2.5 Special Solid Dosage Forms
1.2.6 Press Coated Tablets
1.2.7 Other
1.3 Market by Formulation Technologies
1.3.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Formulation Technologies: 2020 VS 2024 VS 2031
1.3.2 Fluid Bed Granulation
1.3.3 Roller Compaction
1.3.4 Direct Compression
1.3.5 Hot Melt Extrusion
1.3.6 Spray Drying
1.3.7 Microencapsulation
1.4 Market by Application
1.4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth by Application: 2020 VS 2024 VS 2031
1.4.2 Cancer
1.4.3 Hormonal Disorders
1.4.4 Autoimmune Diseases
1.4.5 Neurological Disorders
1.4.6 Pain Management
1.4.7 Other Therapy Areas
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Perspective (2020-2031)
2.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Growth Trends by Region
2.2.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Region (2020-2025)
2.2.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Region (2026-2031)
2.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Dynamics
2.3.1 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Industry Trends
2.3.2 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Drivers
2.3.3 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Challenges
2.3.4 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Revenue
3.1.1 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Revenue (2020-2025)
3.1.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Players (2020-2025)
3.2 Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue
3.4 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Concentration Ratio
3.4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue in 2024
3.5 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Head office and Area Served
3.6 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Product and Application
3.7 Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Breakdown Data by Type
4.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Type (2020-2025)
4.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Type (2026-2031)
5 High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Breakdown Data by Application
5.1 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Historic Market Size by Application (2020-2025)
5.2 Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
6.2 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
6.4 North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
7.2 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
7.4 Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
8.2 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025)
8.4 Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
9.2 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
9.4 Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (2020-2031)
10.2 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025)
10.4 Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.1.4 Catalent Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.1.5 Catalent Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Details
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.2.4 Thermo Fisher Scientific Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Lonza
11.3.1 Lonza Company Details
11.3.2 Lonza Business Overview
11.3.3 Lonza High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.3.4 Lonza Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.3.5 Lonza Recent Development
11.4 Siegfried
11.4.1 Siegfried Company Details
11.4.2 Siegfried Business Overview
11.4.3 Siegfried High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.4.4 Siegfried Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.4.5 Siegfried Recent Development
11.5 Recipharm
11.5.1 Recipharm Company Details
11.5.2 Recipharm Business Overview
11.5.3 Recipharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.5.4 Recipharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.5.5 Recipharm Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.6.4 Boehringer Ingelheim Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.6.5 Boehringer Ingelheim Recent Development
11.7 WuXi AppTech
11.7.1 WuXi AppTech Company Details
11.7.2 WuXi AppTech Business Overview
11.7.3 WuXi AppTech High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.7.4 WuXi AppTech Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.7.5 WuXi AppTech Recent Development
11.8 WuXi Biologics
11.8.1 WuXi Biologics Company Details
11.8.2 WuXi Biologics Business Overview
11.8.3 WuXi Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.8.4 WuXi Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.8.5 WuXi Biologics Recent Development
11.9 Fareva
11.9.1 Fareva Company Details
11.9.2 Fareva Business Overview
11.9.3 Fareva High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.9.4 Fareva Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.9.5 Fareva Recent Development
11.10 Samsung Biologics
11.10.1 Samsung Biologics Company Details
11.10.2 Samsung Biologics Business Overview
11.10.3 Samsung Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.10.4 Samsung Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.10.5 Samsung Biologics Recent Development
11.11 Aenova
11.11.1 Aenova Company Details
11.11.2 Aenova Business Overview
11.11.3 Aenova High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.11.4 Aenova Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.11.5 Aenova Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Details
11.12.2 Delpharm Business Overview
11.12.3 Delpharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.12.4 Delpharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.12.5 Delpharm Recent Development
11.13 Strides Pharma
11.13.1 Strides Pharma Company Details
11.13.2 Strides Pharma Business Overview
11.13.3 Strides Pharma High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.13.4 Strides Pharma Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.13.5 Strides Pharma Recent Development
11.14 Piramal
11.14.1 Piramal Company Details
11.14.2 Piramal Business Overview
11.14.3 Piramal High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.14.4 Piramal Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.14.5 Piramal Recent Development
11.15 Famar
11.15.1 Famar Company Details
11.15.2 Famar Business Overview
11.15.3 Famar High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.15.4 Famar Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.15.5 Famar Recent Development
11.16 Curia
11.16.1 Curia Company Details
11.16.2 Curia Business Overview
11.16.3 Curia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.16.4 Curia Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.16.5 Curia Recent Development
11.17 Jubilant
11.17.1 Jubilant Company Details
11.17.2 Jubilant Business Overview
11.17.3 Jubilant High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.17.4 Jubilant Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.17.5 Jubilant Recent Development
11.18 Vetter
11.18.1 Vetter Company Details
11.18.2 Vetter Business Overview
11.18.3 Vetter High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.18.4 Vetter Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.18.5 Vetter Recent Development
11.19 AGC Pharma Chemicals
11.19.1 AGC Pharma Chemicals Company Details
11.19.2 AGC Pharma Chemicals Business Overview
11.19.3 AGC Pharma Chemicals High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.19.4 AGC Pharma Chemicals Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.19.5 AGC Pharma Chemicals Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Details
11.20.2 Asymchem Business Overview
11.20.3 Asymchem High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Introduction
11.20.4 Asymchem Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
11.20.5 Asymchem Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Tablets
Table 3. Key Players of Hard Gelatine Capsules
Table 4. Key Players of Sublingual Tablets
Table 5. Key Players of Special Solid Dosage Forms
Table 6. Key Players of Press Coated Tablets
Table 7. Key Players of Other
Table 8. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Formulation Technologies (US$ Million): 2020 VS 2024 VS 2031
Table 9. Key Players of Fluid Bed Granulation
Table 10. Key Players of Roller Compaction
Table 11. Key Players of Direct Compression
Table 12. Key Players of Hot Melt Extrusion
Table 13. Key Players of Spray Drying
Table 14. Key Players of Microencapsulation
Table 15. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 18. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2020-2025)
Table 19. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 20. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2026-2031)
Table 21. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Trends
Table 22. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Drivers
Table 23. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Challenges
Table 24. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Restraints
Table 25. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 26. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Players (2020-2025)
Table 27. Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing as of 2024)
Table 28. Ranking of Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Companies by Revenue (US$ Million) in 2024
Table 29. Global 5 Largest Players Market Share by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue (CR5 and HHI) & (2020-2025)
Table 30. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Headquarters and Area Served
Table 31. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Product and Application
Table 32. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Date of Enter into This Industry
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Type (2020-2025) & (US$ Million)
Table 35. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Type (2020-2025)
Table 36. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 37. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Type (2026-2031)
Table 38. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Application (2020-2025) & (US$ Million)
Table 39. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Application (2020-2025)
Table 40. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 41. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Application (2026-2031)
Table 42. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 44. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 45. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 47. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 48. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 49. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 50. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2026-2031) & (US$ Million)
Table 51. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 52. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 53. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 54. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 55. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 56. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 57. Catalent Company Details
Table 58. Catalent Business Overview
Table 59. Catalent High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 60. Catalent Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 61. Catalent Recent Development
Table 62. Thermo Fisher Scientific Company Details
Table 63. Thermo Fisher Scientific Business Overview
Table 64. Thermo Fisher Scientific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 65. Thermo Fisher Scientific Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 66. Thermo Fisher Scientific Recent Development
Table 67. Lonza Company Details
Table 68. Lonza Business Overview
Table 69. Lonza High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 70. Lonza Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 71. Lonza Recent Development
Table 72. Siegfried Company Details
Table 73. Siegfried Business Overview
Table 74. Siegfried High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 75. Siegfried Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 76. Siegfried Recent Development
Table 77. Recipharm Company Details
Table 78. Recipharm Business Overview
Table 79. Recipharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 80. Recipharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 81. Recipharm Recent Development
Table 82. Boehringer Ingelheim Company Details
Table 83. Boehringer Ingelheim Business Overview
Table 84. Boehringer Ingelheim High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 85. Boehringer Ingelheim Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 86. Boehringer Ingelheim Recent Development
Table 87. WuXi AppTech Company Details
Table 88. WuXi AppTech Business Overview
Table 89. WuXi AppTech High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 90. WuXi AppTech Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 91. WuXi AppTech Recent Development
Table 92. WuXi Biologics Company Details
Table 93. WuXi Biologics Business Overview
Table 94. WuXi Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 95. WuXi Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 96. WuXi Biologics Recent Development
Table 97. Fareva Company Details
Table 98. Fareva Business Overview
Table 99. Fareva High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 100. Fareva Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 101. Fareva Recent Development
Table 102. Samsung Biologics Company Details
Table 103. Samsung Biologics Business Overview
Table 104. Samsung Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 105. Samsung Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 106. Samsung Biologics Recent Development
Table 107. Aenova Company Details
Table 108. Aenova Business Overview
Table 109. Aenova High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 110. Aenova Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 111. Aenova Recent Development
Table 112. Delpharm Company Details
Table 113. Delpharm Business Overview
Table 114. Delpharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 115. Delpharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 116. Delpharm Recent Development
Table 117. Strides Pharma Company Details
Table 118. Strides Pharma Business Overview
Table 119. Strides Pharma High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 120. Strides Pharma Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 121. Strides Pharma Recent Development
Table 122. Piramal Company Details
Table 123. Piramal Business Overview
Table 124. Piramal High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 125. Piramal Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 126. Piramal Recent Development
Table 127. Famar Company Details
Table 128. Famar Business Overview
Table 129. Famar High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 130. Famar Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 131. Famar Recent Development
Table 132. Curia Company Details
Table 133. Curia Business Overview
Table 134. Curia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 135. Curia Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 136. Curia Recent Development
Table 137. Jubilant Company Details
Table 138. Jubilant Business Overview
Table 139. Jubilant High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 140. Jubilant Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 141. Jubilant Recent Development
Table 142. Vetter Company Details
Table 143. Vetter Business Overview
Table 144. Vetter High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 145. Vetter Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 146. Vetter Recent Development
Table 147. AGC Pharma Chemicals Company Details
Table 148. AGC Pharma Chemicals Business Overview
Table 149. AGC Pharma Chemicals High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 150. AGC Pharma Chemicals Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 151. AGC Pharma Chemicals Recent Development
Table 152. Asymchem Company Details
Table 153. Asymchem Business Overview
Table 154. Asymchem High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 155. Asymchem Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 156. Asymchem Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
Table 160. Authors List of This Report
List of Figures
Figure 1. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Picture
Figure 2. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Type: 2024 VS 2031
Figure 4. Tablets Features
Figure 5. Hard Gelatine Capsules Features
Figure 6. Sublingual Tablets Features
Figure 7. Special Solid Dosage Forms Features
Figure 8. Press Coated Tablets Features
Figure 9. Other Features
Figure 10. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Comparison by Formulation Technologies (2020-2031) & (US$ Million)
Figure 11. Fluid Bed Granulation Features
Figure 12. Roller Compaction Features
Figure 13. Direct Compression Features
Figure 14. Hot Melt Extrusion Features
Figure 15. Spray Drying Features
Figure 16. Microencapsulation Features
Figure 17. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Application (2020-2031) & (US$ Million)
Figure 18. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Application: 2024 VS 2031
Figure 19. Cancer Case Studies
Figure 20. Hormonal Disorders Case Studies
Figure 21. Autoimmune Diseases Case Studies
Figure 22. Neurological Disorders Case Studies
Figure 23. Pain Management Case Studies
Figure 24. Other Therapy Areas Case Studies
Figure 25. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Report Years Considered
Figure 26. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 27. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 28. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region: 2024 VS 2031
Figure 29. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Players in 2024
Figure 30. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 31. The Top 10 and 5 Players Market Share by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue in 2024
Figure 32. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 34. United States High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Canada High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 38. Germany High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. France High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. U.K. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Italy High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Russia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Ireland High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2020-2031)
Figure 46. China High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Japan High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. South Korea High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Southeast Asia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. India High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Australia & New Zealand High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 54. Mexico High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Brazil High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 58. Israel High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 59. Saudi Arabia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 60. UAE High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 61. Catalent Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 62. Thermo Fisher Scientific Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 63. Lonza Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 64. Siegfried Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 65. Recipharm Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 67. WuXi AppTech Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 68. WuXi Biologics Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 69. Fareva Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 70. Samsung Biologics Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 71. Aenova Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 72. Delpharm Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 73. Strides Pharma Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 74. Piramal Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 75. Famar Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 76. Curia Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 77. Jubilant Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 78. Vetter Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 79. AGC Pharma Chemicals Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 80. Asymchem Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed
Table 1. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Tablets
Table 3. Key Players of Hard Gelatine Capsules
Table 4. Key Players of Sublingual Tablets
Table 5. Key Players of Special Solid Dosage Forms
Table 6. Key Players of Press Coated Tablets
Table 7. Key Players of Other
Table 8. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Formulation Technologies (US$ Million): 2020 VS 2024 VS 2031
Table 9. Key Players of Fluid Bed Granulation
Table 10. Key Players of Roller Compaction
Table 11. Key Players of Direct Compression
Table 12. Key Players of Hot Melt Extrusion
Table 13. Key Players of Spray Drying
Table 14. Key Players of Microencapsulation
Table 15. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 18. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2020-2025)
Table 19. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 20. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2026-2031)
Table 21. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Trends
Table 22. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Drivers
Table 23. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Challenges
Table 24. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Restraints
Table 25. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 26. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Players (2020-2025)
Table 27. Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing as of 2024)
Table 28. Ranking of Global Top High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Companies by Revenue (US$ Million) in 2024
Table 29. Global 5 Largest Players Market Share by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue (CR5 and HHI) & (2020-2025)
Table 30. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Headquarters and Area Served
Table 31. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Product and Application
Table 32. Global Key Players of High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing, Date of Enter into This Industry
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Type (2020-2025) & (US$ Million)
Table 35. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Type (2020-2025)
Table 36. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 37. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Type (2026-2031)
Table 38. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Application (2020-2025) & (US$ Million)
Table 39. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Application (2020-2025)
Table 40. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 41. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue Market Share by Application (2026-2031)
Table 42. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 44. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 45. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 47. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 48. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 49. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 50. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Region (2026-2031) & (US$ Million)
Table 51. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 52. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 53. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 54. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 55. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 56. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 57. Catalent Company Details
Table 58. Catalent Business Overview
Table 59. Catalent High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 60. Catalent Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 61. Catalent Recent Development
Table 62. Thermo Fisher Scientific Company Details
Table 63. Thermo Fisher Scientific Business Overview
Table 64. Thermo Fisher Scientific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 65. Thermo Fisher Scientific Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 66. Thermo Fisher Scientific Recent Development
Table 67. Lonza Company Details
Table 68. Lonza Business Overview
Table 69. Lonza High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 70. Lonza Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 71. Lonza Recent Development
Table 72. Siegfried Company Details
Table 73. Siegfried Business Overview
Table 74. Siegfried High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 75. Siegfried Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 76. Siegfried Recent Development
Table 77. Recipharm Company Details
Table 78. Recipharm Business Overview
Table 79. Recipharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 80. Recipharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 81. Recipharm Recent Development
Table 82. Boehringer Ingelheim Company Details
Table 83. Boehringer Ingelheim Business Overview
Table 84. Boehringer Ingelheim High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 85. Boehringer Ingelheim Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 86. Boehringer Ingelheim Recent Development
Table 87. WuXi AppTech Company Details
Table 88. WuXi AppTech Business Overview
Table 89. WuXi AppTech High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 90. WuXi AppTech Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 91. WuXi AppTech Recent Development
Table 92. WuXi Biologics Company Details
Table 93. WuXi Biologics Business Overview
Table 94. WuXi Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 95. WuXi Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 96. WuXi Biologics Recent Development
Table 97. Fareva Company Details
Table 98. Fareva Business Overview
Table 99. Fareva High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 100. Fareva Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 101. Fareva Recent Development
Table 102. Samsung Biologics Company Details
Table 103. Samsung Biologics Business Overview
Table 104. Samsung Biologics High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 105. Samsung Biologics Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 106. Samsung Biologics Recent Development
Table 107. Aenova Company Details
Table 108. Aenova Business Overview
Table 109. Aenova High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 110. Aenova Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 111. Aenova Recent Development
Table 112. Delpharm Company Details
Table 113. Delpharm Business Overview
Table 114. Delpharm High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 115. Delpharm Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 116. Delpharm Recent Development
Table 117. Strides Pharma Company Details
Table 118. Strides Pharma Business Overview
Table 119. Strides Pharma High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 120. Strides Pharma Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 121. Strides Pharma Recent Development
Table 122. Piramal Company Details
Table 123. Piramal Business Overview
Table 124. Piramal High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 125. Piramal Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 126. Piramal Recent Development
Table 127. Famar Company Details
Table 128. Famar Business Overview
Table 129. Famar High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 130. Famar Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 131. Famar Recent Development
Table 132. Curia Company Details
Table 133. Curia Business Overview
Table 134. Curia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 135. Curia Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 136. Curia Recent Development
Table 137. Jubilant Company Details
Table 138. Jubilant Business Overview
Table 139. Jubilant High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 140. Jubilant Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 141. Jubilant Recent Development
Table 142. Vetter Company Details
Table 143. Vetter Business Overview
Table 144. Vetter High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 145. Vetter Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 146. Vetter Recent Development
Table 147. AGC Pharma Chemicals Company Details
Table 148. AGC Pharma Chemicals Business Overview
Table 149. AGC Pharma Chemicals High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 150. AGC Pharma Chemicals Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 151. AGC Pharma Chemicals Recent Development
Table 152. Asymchem Company Details
Table 153. Asymchem Business Overview
Table 154. Asymchem High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Product
Table 155. Asymchem Revenue in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025) & (US$ Million)
Table 156. Asymchem Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
Table 160. Authors List of This Report
List of Figures
Figure 1. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Picture
Figure 2. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Type: 2024 VS 2031
Figure 4. Tablets Features
Figure 5. Hard Gelatine Capsules Features
Figure 6. Sublingual Tablets Features
Figure 7. Special Solid Dosage Forms Features
Figure 8. Press Coated Tablets Features
Figure 9. Other Features
Figure 10. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size Comparison by Formulation Technologies (2020-2031) & (US$ Million)
Figure 11. Fluid Bed Granulation Features
Figure 12. Roller Compaction Features
Figure 13. Direct Compression Features
Figure 14. Hot Melt Extrusion Features
Figure 15. Spray Drying Features
Figure 16. Microencapsulation Features
Figure 17. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size by Application (2020-2031) & (US$ Million)
Figure 18. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Application: 2024 VS 2031
Figure 19. Cancer Case Studies
Figure 20. Hormonal Disorders Case Studies
Figure 21. Autoimmune Diseases Case Studies
Figure 22. Neurological Disorders Case Studies
Figure 23. Pain Management Case Studies
Figure 24. Other Therapy Areas Case Studies
Figure 25. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Report Years Considered
Figure 26. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 27. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 28. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region: 2024 VS 2031
Figure 29. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Players in 2024
Figure 30. Global High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 31. The Top 10 and 5 Players Market Share by High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Revenue in 2024
Figure 32. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. North America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 34. United States High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Canada High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Europe High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 38. Germany High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. France High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. U.K. High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Italy High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Russia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Ireland High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Region (2020-2031)
Figure 46. China High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Japan High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. South Korea High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Southeast Asia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. India High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Australia & New Zealand High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Latin America High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 54. Mexico High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Brazil High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Middle East & Africa High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Share by Country (2020-2031)
Figure 58. Israel High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 59. Saudi Arabia High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 60. UAE High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 61. Catalent Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 62. Thermo Fisher Scientific Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 63. Lonza Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 64. Siegfried Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 65. Recipharm Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 67. WuXi AppTech Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 68. WuXi Biologics Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 69. Fareva Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 70. Samsung Biologics Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 71. Aenova Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 72. Delpharm Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 73. Strides Pharma Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 74. Piramal Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 75. Famar Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 76. Curia Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 77. Jubilant Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 78. Vetter Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 79. AGC Pharma Chemicals Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 80. Asymchem Revenue Growth Rate in High-Potent Oral Solid Dosage (HP-OSD) Contract Manufacturing Business (2020-2025)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232